BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

All News

FDA Briefs

Oncology Icons

Special Reports

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Precision Medicine

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

A 76-Year-Old Woman with Newly Diagnosed MF

Case Based Peer Perspectives

Advice for Clinicians Treating Patients With MF

Videos

Anthony Hunter, MD, presents the case of a 76-year-old woman with newly diagnosed myelofibrosis for discussion and reviews the available treatment options, including the recently FDA approved JAK inhibitor momelotinib.

Anthony Hunter, MD, presents the case of a 76-year-old woman with newly diagnosed primary myelofibrosis with a JAK2 mutation, for which he recommended treatment with momelotinib due to her moderate anemia and refusal of transplant.

Case Presentation: A 76-Year-Old Woman With Newly-Diagnosed Myelofibrosis (MF)

Defining Myelofibrosis

Myelofibrosis can be categorized as primary (developing de novo) or secondary (arising in patients with pre-existing MPNs), and it further distinguishes between proliferative and cytopenic types, with each type having its unique diagnostic criteria and implications for treatment.

Types of Myelofibrosis

Anthony Hunter, MD, details the primary goals when treating a typical patient with myelofibrosis, such as improving symptoms like weight loss and fatigue, addressing anemia, and, more recently, striving to extend survival, with treatments like JAK inhibitors showing potential for improving overall survival in patients.

Treatment Goals for Patients With MF

Dr Anthony Hunter explains that the decision to initiate therapy in patients with myelofibrosis is individualized, considering factors like symptoms and risk stratification; early treatment with JAK inhibitors is crucial for symptom control, but allogeneic stem cell transplant remains the only potential curative therapy, particularly for higher-risk patients.

When to Initiate Therapy in Patients With MF

Momelotinib, a recently approved treatment for myelofibrosis, targets multiple pathways,and offers a promising approach to improve anemia, especially in patients who did not respond optimally to previous JAK inhibitors.

Rationale for Treatment With Momelotinib in Patients With MF

Anthony Hunter, MD, explains that anemia is a common complication in patients with myelofibrosis, often worsening over time; treatment strategies involve monitoring, transfusion support, and considering additional anemia-directed agents.

Managing Anemia in Patients With MF Receiving Momelotinib

The SIMPLIFY-1 trial investigated the use of momelotinib in JAK inhibitor-naive patients with myelofibrosis, primarily symptomatic with spleen enlargement, hepatomegaly, or anemia; results showed momelotinib led to improved transfusion independence, reduced transfusion burden, and decreased anemia compared to ruxolitinib.

Momelotinib in MF: Data from the SIMPLIFY-1 Trial

Dr Anthony Hunter reviews the other three approved JAK inhibitors for treatment of myelofibrosis: ruxolitinib, fedratinib, and pacritinib.

Other Therapies Approved for Patients With MF

Anthony Hunter, MD, closes his discussion by sharing advice for clinicians treating patients with myelofibrosis.

Advice for Clinicians Treating Patients With MF

EP: 1.Case Presentation: A 76-Year-Old Woman With Newly-Diagnosed Myelofibrosis (MF)

EP: 2.Defining Myelofibrosis

EP: 3.Types of Myelofibrosis

EP: 4.Treatment Goals for Patients With MF

EP: 5.When to Initiate Therapy in Patients With MF

EP: 6.Rationale for Treatment With Momelotinib in Patients With MF

EP: 7.Managing Anemia in Patients With MF Receiving Momelotinib

EP: 8.Momelotinib in MF: Data from the SIMPLIFY-1 Trial

EP: 9.Other Therapies Approved for Patients With MF

EP: 10.Advice for Clinicians Treating Patients With MF